Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in ...
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study ...
Aebi Schmidt Holding AG (NASDAQ: AEBI) (“Aebi Schmidt Group” or the “Company”), a world-class specialty vehicles leader, announced that its Board of Directors declared a quarterly dividend of $0.025 ...
52mOpinion
Opinion | Kaveri To J-20, How China Overtook India In A 40-Year-Old Race To Build Fighter Jets
Both launched ambitious military jet engine programmes during the 1980s. Both depended heavily on Soviet and Russian ...
JCPenney catalogs, an old baseball, essays to the future. Or sometimes just boring paperwork. In making these Bicentennial ...
SOLAI Limited (NYSE: SLAI) ("SOLAI" or the "Company") (previously known as "BIT Mining Limited"), a technology-driven personal AI and digital infrastructure provider, today announced that on July 16, ...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, has expanded their clinical trial collaboration with Merck (known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results